Oxaliplatin induces immunogenic cells death and enhances therapeutic efficacy of checkpoint inhibitor in a model of murine lung carcinoma

Sun, Fengfei; Cui, Lijuan; Li, Tingting; Chen, Silin; Jun-mei, Song; Li, Dezhi

doi:10.1080/10799893.2019.1655050

Cited by 63 publications

(54 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Guido Kroemer's team showed that a continuous exposure to oxaliplatin (from 15 to 300 µM, depending on the cell type) induces CRT exposure, ATP and HMGB1 release by different types of cancer cells, such as murine colon cancer (CT26), fibrosarcoma (MCA205) or human bone osteosarcoma (U2OS) [6,31,33,75]. These results were confirmed in human and murine pancreatic tumor cell lines (Panc-1 and Pan02), in murine mammary adenocarcinoma (TSA), in murine glioma cells (KR158) and in murine lung carcinoma (LLC) [76][77][78][79]. In our recent work, we performed in vitro experiments on CT26 murine colon cancer cells with a brief exposure of cancer cells to chemotherapy to reproduce clinical settings and, in particular, hyperthermic intraperitoneal chemotherapy (HIPEC).…”

Section: Direct Effectsmentioning

confidence: 80%

“…Concerning cisplatin, CRT exposure, ATP and HMGB1 release can be observed or not, depending on the cell type and/or the concentrations used and/or treatment duration [12,25,31,33,[81][82][83]. In LLC, one study reports that 24 h exposure to 20 µM of cisplatin cannot induce immunogenic cell death features [77], whereas in another study, treatment of these cells with 2.5 µM during 24 or 48 h induced ATP release and CRT exposure, but not HMGB1 release [82]. In CT26 cells, cisplatin can induce HMGB1 and ATP release, but not CRT exposure [33,83].…”

Section: Direct Effectsmentioning

confidence: 99%

See 1 more Smart Citation

Platinum Derivatives Effects on Anticancer Immune Response

et al. 2019

View full text Add to dashboard Cite

Along with surgery and radiotherapy, chemotherapeutic agents belong to the therapeutic arsenal in cancer treatment. In addition to their direct cytotoxic effects, these agents also impact the host immune system, which might enhance or counteract their antitumor activity. The platinum derivative compounds family, mainly composed of carboplatin, cisplatin and oxaliplatin, belongs to the chemotherapeutical arsenal used in numerous cancer types. Here, we will focus on the effects of these molecules on antitumor immune response. These compounds can induce or not immunogenic cell death (ICD), and some strategies have been found to induce or further enhance it. They also regulate immune cells' fate. Platinum derivatives can lead to their activation. Additionally, they can also dampen immune cells by selective killing or inhibiting their activity, particularly by modulating immune checkpoints' expression.Cell death is characterized by morphological alterations that have been historically used by The Nomenclature Committee on Cell Death (NCCD) to classify this cellular process into three different forms: type I or apoptosis, type II or autophagy, and type III or necrosis. Although limited, this morphological classification remains widely used, independently of essential molecular aspects of the cell death process. New NCCD classifications focus on molecular mechanisms and on the biochemistry of intracellular signalization effectors. Currently, it is clear that connections and overlaps exist between the different types of cell death. The majority of chemotherapeutic drugs are known to induce apoptosis or necrosis. Engagement of a particular type of cell death depends on the stress type, interaction between induction factors, genetic cell background, organelle content and enzymatic proteins arsenal [3,4].The action of chemotherapy relies not only on its cytotoxic effect on cancer cells, but also on its ability to affect immune cells.

show abstract

Section: Direct Effectsmentioning

confidence: 80%

Section: Direct Effectsmentioning

confidence: 99%

Platinum Derivatives Effects on Anticancer Immune Response

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Significant increase of IL-1beta (M1 cytokine) and significant decrease of IL-1ra (M2 cytokine) production by alveolar macrophages isolated from BALF after platinum-based chemotherapy were demonstrated in patients with small cell lung cancer from the Japanese cohort (190). It was also found that platinum-containing drug oxaliplatin induced immunogenic cell death (ICD) in LLC cells, activating dendritic cells with CD80+CD86+ phenotype and enhancing cytotoxic CD8+ T cells in LLC tumor tissues, which resulted in tumor regression in a mouse model of lung cancer (191). However, no effect of oxaliplatin on macrophages was investigated in this study (191).…”

Section: Tams and Lung Cancer Treatmentmentioning

confidence: 84%

“…It was also found that platinum-containing drug oxaliplatin induced immunogenic cell death (ICD) in LLC cells, activating dendritic cells with CD80+CD86+ phenotype and enhancing cytotoxic CD8+ T cells in LLC tumor tissues, which resulted in tumor regression in a mouse model of lung cancer (191). However, no effect of oxaliplatin on macrophages was investigated in this study (191).…”

Section: Tams and Lung Cancer Treatmentmentioning

confidence: 84%

Tumor-Associated Macrophages in Human Breast, Colorectal, Lung, Ovarian and Prostate Cancers

et al. 2020

View full text Add to dashboard Cite

Tumor-associated macrophages (TAMs) are major innate immune cells that constitute up to 50% of the cell mass of human tumors. TAMs are highly heterogeneous cells that originate from resident tissue-specific macrophages and from newly recruited monocytes. TAMs' variability strongly depends on cancer type, stage, and intratumor heterogeneity. Majority of TAMs are programmed by tumor microenvironment to support primary tumor growth and metastatic spread. However, TAMs can also restrict tumor growth and metastasis. In this review, we summarized the knowledge about the role of TAMs in tumor growth, metastasis and in the response to cancer therapy in patients with five aggressive types of cancer: breast, colorectal, lung, ovarian, and prostate cancers that are frequently metastasize into distant organs resulting in high mortality of the patients. Two major TAM parameters are applied for the evaluation of TAM correlation with the cancer progression: total amount of TAMs and specific phenotype of TAMs identified by functional biomarkers. We summarized the data generated in the wide range of international patient cohorts on the correlation of TAMs with clinical and pathological parameters of tumor progression including lymphatic and hematogenous metastasis, recurrence, survival, therapy efficiency. We described currently available biomarkers for TAMs that can be measured in patients' samples (tumor tissue and blood). CD68 is the major biomarker for the quantification of total TAM amounts, while transmembrane receptors (stabilin-1, CD163, CD206, CD204, MARCO) and secreted chitinase-like proteins (YKL-39, YKL-40) are used as biomarkers for the functional TAM polarization. We also considered that specific role of TAMs in tumor progression can depend on the localization in the intratumoral compartments. We have made the conclusion for the role of TAMs in primary tumor growth, metastasis, and therapy sensitivity for breast, colorectal, lung, ovarian, and prostate cancers. In contrast to other cancer types, majority of clinical studies indicate that TAMs in colorectal cancer have protective role for the patient and interfere with primary tumor growth

show abstract

“…BMDCs, and RAW264.7, GMK-AH1, JAWSII cells Niikura et al, 2013;Orlowski et al, 2018 MHC, major histocompatibility complex;DC, dendritic cell;GST, gold sodium thiomalate;IFN-γ, interferon-γ;TLR, toll-like receptor. bleomycin, the alkylating agent cyclophosphamide, bortezomib, as well as the metal-based agent oxaliplatin (Tesniere et al, 2010;Kroemer et al, 2013;Sun et al, 2019;Zhou et al, 2019). Although type II ICD inducers are rare, they have recently been identified in preclinical metal-containing compounds (Wong et al, 2015).…”

Section: Gold Compounds Induce Immunogenic Cell Deathmentioning

confidence: 99%

Recent Advances of Gold Compounds in Anticancer Immunity

et al. 2020

View full text Add to dashboard Cite

In recent years, gold compounds have gained more and more attentions in the design of new metal anticancer drugs. Numerous researches have reported that gold compounds, in addition to their widely studied cytotoxic antitumor effects, also reverse tumor immune escape and directly facilitate the functions of immune cells, leading to enhanced anticancer effects. This review mainly summarizes our current understandings of antitumor effects of gold drugs and their relationships with various aspects of antitumor immunity, including innate immunity, adaptive immunity, immunogenic cell death, and immune checkpoints, as well as their roles in adverse effects. Some recent examples of anticancer gold compounds are highlighted. The property of gold compounds is expected to combine with anticancer immunotherapy, such as immune checkpoint inhibitors, to develop new anticancer therapeutic strategies.

show abstract

Oxaliplatin induces immunogenic cells death and enhances therapeutic efficacy of checkpoint inhibitor in a model of murine lung carcinoma

Cited by 63 publications

References 31 publications

Platinum Derivatives Effects on Anticancer Immune Response

Platinum Derivatives Effects on Anticancer Immune Response

Tumor-Associated Macrophages in Human Breast, Colorectal, Lung, Ovarian and Prostate Cancers

Recent Advances of Gold Compounds in Anticancer Immunity

Contact Info

Product

Resources

About